Inside the myeloma journey

Clonal heterogeneity and evolution

[Space for short written/referenced copy on clonal heterogeneity and evolution in myeloma]

Figure 1. Schematic showing progression from MGUS to symptomatic MM and advanced disease, characterized by increasing clonal heterogeneity driven by genetic diversification, competition, and selective pressures, with rising tumor burden and clinical symptoms. MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; PCL, plasma cell leukemia; SMM, smoldering MM.

What mechanisms enable multiple myeloma (MM) to evade immune control and develop drug resistance? [EXPERT NAME] discusses clonal escape and antigen heterogeneity, highlighting the important role these mechanisms play in myeloma disease progression and treatment resistance.

Genetic abnormalities in MM

[Space for short written/referenced copy on genetic changes/abnormalities in multiple myeloma]

How do genetic and cytogenetic abnormalities contribute to the complexity of MM? [EXPERT NAME] discusses the spectrum of genomic changes seen in myeloma and how cytogenetic features inform our understanding of disease behavior and risk.

Figure 2. Schematic showing multistep molecular pathogenesis of MM. Primary and secondary genetic events involved in the MM transformation and progression from the precursor disease entities, such as MGUS and SMM to MM, and eventually to extramedullary myeloma / PCL. GC, germinal center; IGH, immunoglobulin heavy chain; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; PCL, plasma cell leukemia; SMM, smoldering MM.

Dynamic risk assessment over the disease course

[Space for short written/referenced copy on the importance of dynamic risk assessment over the disease course in multiple myeloma]

How does risk evolve over time in MM? [EXPERT NAME] discusses dynamic risk assessment across the disease course, highlighting how changes in clinical features and genomic and response-based biomarkers inform ongoing decision-making.

[Linking text to next tab discussing clinical relevance of minimal disease activity]

References

Incorporating minimal residual disease detection in clinical decision-making

[Space for short written/referenced copy on the use of minimal residual disease in clinical trials and the importance of incorporating this measure into clinical practice]

[Description here, may include quote or upfront question followed by sentence summarizing the topic of the recording]

Patient attrition over time: Key contributing factors

[Space for short written/referenced copy on patient attrition over time]

[Space for figures/visuals displaying patient attrition rates over time]

[Space for short written/referenced copy on what has led to improvements in attrition rates in the last decade, what can be done to further improve attrition rates now, and how these may continue to improve in the future]

Impact of frailty on outcomes and quality of life

[Space for short written/referenced copy on the impact of frailty on outcomes and quality of life in MM]

Possible formats:

• KOL interviews
• Figures alongside written copy
• Use of call outs to highlight key messages

This page could be linked to an interactive case study page.

KOL-led content

Possible topics to include:

• Increasing complexity of care decision-making in MM
• Balancing disease biology, patient factors, and treatment goals
• Uncertainty and variability in real-world practice
• The evolving role of multidisciplinary care teams

Possible formats:

• KOL interviews
• Roundtable/webinar
• Podcasts alongside surround copy
• Video discussions

Possible topics to include:

• Traditional clinical outcomes vs patient centric outcomes
• The role of patient-reported outcomes in understanding disease impact
• Strengths and limitations of response-based metrics
• Challenges in capturing long-term disease burden

Possible formats:

• KOL interviews
• Figures alongside written copy
• Downloadable presentations